The anti-helminthic drug suramin inhibited the basal high-affinity GTPase activity of both C6 BUl glioma and NG 108-15 neuroblastoma x glioma hybrid-cell membranes with an IC50 (concentration causing halfmaximal inhibition) value close to 30 jug/ml. This effect was shown to occur via a non-competitive mechanism in which the binding affinity of the G-proteins for GTP was not altered, but the maximal velocity of the subsequent hydrolysis was reduced. In NG 108-15 membranes, both opioid peptides and foetal-calf serum stimulated high-affinity GTPase activity in a pertussis-toxin-sensitive manner. These effects have previously been shown to be mediated by different G-proteins [McKenzie, Kelly, Unson, Spiegel & Milligan (1988) Biochem. J. 249,[653][654][655][656][657][658][659]. Suramin completely prevented the opioid-peptide-stimulated increase in GTP hydrolysis, but did not prevent the opioid peptide from binding to its receptor. Suramin, however, did not block the foetal-calf-serum-stimulated GTPase response. This selective action of suramin provides further evidence for distinct roles for two separate pertussis-toxin-sensitive G-proteins in signal transduction in NG 108-15 membranes and provides the first evidence for a selective effect of a drug on the functions of different G-proteins.
INTRODUCTION
Hormones, neurotransmitters and growth factors which act to modulate levels of intracellular second messengers do so via the intermediacy of members of a family of guanine-nucleotide-binding proteins (G-proteins) [1, 2] . These include G. and G1, which respectively mediate stimulation and inhibition of adenylate cyclase [3] , transducin, which couples the photon receptor rhodopsin to a cyclic GMP phosphodiesterase [4] , and G. [5, 6] , which may couple receptors to the modulation of Ca2l channels. Each of these transducer proteins consists of three non-identical subunits, a, , and y, and it is the a-subunit which is unique to each individual member of the family. Although the a-subunits of these proteins are distinct, they are highly homologous [7, 8] . Attempts to distinguish between them thus far have been based on the ability of certain exotoxins produced by either Vibrio cholerae or Bordetella pertussis to catalyse selectively specific ADP-ribosylation of these proteins [9, 10] or, more recently, on the use of specific polyclonal and anti-peptide antisera [11] [12] [13] [14] .
It would be useful if selective drugs were available which could discriminate interactions between receptors and particular G-proteins. However, to date no such drugs have been described, and the marked sequence homology between the a-subunits of different G-proteins limits the potentially selective sites of drug interaction.
The anti-helminthic drug suramin is a polyanionic compound which has been reported to interact nonspecifically with a wide range of plasma proteins [15] . It has also been described as a relatively selective competitive antagonist at a range of growth-factor receptors [16, 17] . Here we demonstrate that suramin can noncompetitively inhibit the GTPase activity of certain Gproteins such as G1 and hence disrupt the function of 8-opioid receptors which couple to this G-protein in the neuroblastoma x glioma hybrid cell line NG 108-15. However, suramin does not inhibit the receptor-stimulated GTPase activity of a second pertussis-toxin-sensitive G-protein which has been shown to interact with a growth-factor receptor in this cell line [18] .
MATERIALS AND METHODS Materials
Foetal-calf serum was from Gibco and was heatinactivated by treatment at 56°C for 1 h before use.
[y-32P]GTP was prepared as described elsewhere [19] taining 5 % (v/v) foetal-calf serum and 100 units of penicillin and streptomycin/ml as previously described [20] . Neuroblastomaxglioma hybrid NG 108-15 cells, which were kindly given by Dr. W. Klee, National Institute of Mental Health, Bethesda, MD, U.S.A., were grown as in [13] , except that the concentration of foetalcalf serum was 10% (v/v). Cells were harvested at confluency, and cell pastes and membranes were prepared [21] and stored at -70°C until use.
GTPase activities of the membranes were measured as previously described [18] . In all cases, receptor-stimulated (DALAMID) . Protein was measured as described by Lowry et al. [22] , with bovine serum albumin as standard.
RESULTS
The basal rate of hydrolysis of GTP by high-affinity GTPases in membranes prepared from cells of the rat glioma cell line C6 BUl was characterized by an apparent Km of 0.24 + 0.03,M and a Vmax of 36.6 + 1.9 pmol/min per mg of membrane protein (means + S.D.). This activity was inhibited by suramin ( Fig. 1 ). In the presence of suramin at 30 jug/ml the estimated Vmax for the reaction was reduced to 15.6 + 0.8 pmol/min per mg of protein, but the apparent Km was not signficantly affected ( Table  1 ), indicating that suramin was acting in a noncompetitive manner to inhibit the hydrolysis, but not the binding, of GTP (Fig. 2) . A further increase of suramin concentration to 100 ,sg/ml further reduced the Vmax to 11.2 + 1.3 pmol/min per mg of protein, with little effect on the estimated Km for GTP (0.34 + 0.08 ,M). Similar effects of suramin were noted on the basal GTPase activity of NG 108-15 cell membranes. With an IC50 of 30 jug/ml, suramin produced a reduction in Vmax with no substantial effect on the apparent Km for GTP ( Table 1) . As we have previously shown that two separate pertussistoxin-sensitive G-proteins mediate the responses to opioid peptides and to foetal-calf serum in NG 108-15 cell membranes [23] , we then decided to examine the effects of suramin on the receptor-stimulated GTPase activities associated with these two ligands. Stimulation of the high-affinity GTPase activity over the basal level was observed with the synthetic enkephalin DADLE (Fig. 3) . The EC50 for this response was 21 nM, and the response was saturated at concentrations below 1 /#M.
However, in the presence of suramin at 100 ,ug/ml, no significant DADLE-stimulated high-affinity GTPase activity was observed at concentrations of the peptide up to 1 mm, a concentration approximately five orders of magnitude higher than the EC50 value noted in the absence of the inhibitor. To check that suramin was not acting as a potent antagonist at the 6-opioid-receptorbinding site, we In contrast with the opioid response, foetal-calfserum-mediated stimulation of high-affinity GTPase activity-over the basal levels in NG108-15 membranes was not decreased in the presence of suramin (Fig. 4) . Two effects of suramin were, however, observed. Firstly, [GTPI (pM) 
DISCUSSION
In the present study we demonstrate interactions of the anti-helminthic drug suramin with pertussis-toxin-sensitive G-proteins in both the neuroblastoma x glioma hybrid cell line NG 108-15 and the glioma cell line C6 BUl. NG108-15 cells express both &-opioid receptorsand poorly characterized growth-factor receptors which function by communicating with individual pertussistoxin-sensitive G-proteins [23] . Whereas the C6 cell line is one of the parental lines of the NG108-15 hybrid, it does not routinely express receptors for opioid peptides [24] . It does, however, respond to foetal-calf serum in a pertussis-toxin-sensitive manner [18] . Suramin equipotently inhibited the basal rate of hydrolysis of GTP by high-affinity GTPases in the membranes of both these cell lines ( Fig. 1 and Table 1 ). In both cases this action was shown to occur via a non-competitive interaction. As suramin is able to interact in a non-selective manner with a wide range of proteins [15] , then this observation would be of only very limited interest if we were unable to demonstrate a degree of selectivity of this drug in its effects on different receptor-G-protein interactions. This we have been able to achieve by comparing the ability of opioid peptides and foetal-calf serum to stimulate GTPase activity in NG 108-15 membranes. In this cell line these two ligands interact with separate pertussistoxin-sensitive G-proteins which both have at-subunits of Mr near 40 kDa [23] . These conclusions were based on (1) the complete additivity of GTPase stimulations by Vol. 251 coupling, it is enlightening that, despite the very large degree of homology between the a-subunits of different G-proteins, this drug can display a degree of discrimination between them. This raises the important possibility that drugs with a high degree of selectivity for different G-proteins and G-protein-receptor interactions could be designed.
